Welcome to our cancer immunotherapy portal!

Roche is taking a dynamic approach to research by exploring how to modulate the antitumour immune response. Find out more about the principles of this new treatment option and why bladder and lung cancer are a focus of exploration in this context.

Indications

Immunotherapy in bladder cancer

Learn more about lung and bladder cancer and which future role cancer immunotherapy might play in the management of these diseases. Here

Cancer immunotherapy

Cancer Immunotherapy Principles

Find out how the immune system fights cancer and how the tumour tries to evade this. Here

The PD-L1 pathway

The PD-L1 pathway

Learn more about the PD-L1 pathway and what makes it an interesting medical target. Here

Clinical studies

Clinical Studies with atezolizumab in Switzerland

This content is intended for Swiss health care professionals who participate with their institution in clinical studies of Roche in bladder and lung cancer, wish to participate in future studies or wish to assign a patient to an ongoing study. Learn more Here

Testing

testing in bladder cancer

Learn more about PD-L1 as a potential biomarker
Here

Contact

Contact us

Do you have any questions about cancer immunotherapy or the PD-L1 pathway?
Contact the Roche Medical Team. Here

adverse-events-reporting-ger
Please send reports about adverse events to switzerland.ds@roche.com.